Rosenstock, Julio http://orcid.org/0000-0001-8324-3275
Cheng, Alice
Ritzel, Robert http://orcid.org/0000-0001-5417-4135
Bosnyak, Zsolt
Devisme, Christine
Cali, Anna M.G.
Sieber, Jochen
Stella, Peter
Wang, Xiangling
Frías, Juan P.
Roussel, Ronan http://orcid.org/0000-0003-2292-8363
Bolli, Geremia B. http://orcid.org/0000-0003-4966-4003
Clinical trials referenced in this document:
Documents that mention this clinical trial
131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial
https://doi.org/10.2337/db19-131-lb
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial (Results)
https://doi.org/10.2337/dc18-0559
Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study
https://doi.org/10.2337/db18-301-or
1098-P: Treatment Satisfaction with Gla-300, IDeg-100, and Gla-100 in Insulin-Naïve T2DM: The BRIGHT and EDITION 3 Trials
https://doi.org/10.2337/db19-1098-p
Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study
https://doi.org/10.2337/db18-1029-p
Lower Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM on Oral Antihyperglycemic Therapy ± GLP-1RA—The BRIGHT Randomized Study
https://doi.org/10.2337/db18-1032-p
146-OR: Differences in HbA1c-Lowering Effect and Hypoglycemia Risk between Gla-300 and IDeg According to Renal Function in the BRIGHT Trial
https://doi.org/10.2337/db19-146-or
1090-P: Reaching ADA Glycemic Targets without Hypoglycemia during Titration with Gla-300 and IDeg in T2DM: Exploratory Analyses from BRIGHT
https://doi.org/10.2337/db19-1090-p
1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes
https://doi.org/10.2337/db19-1095-p
Documents that mention this clinical trial
131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial
https://doi.org/10.2337/db19-131-lb
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial (Results)
https://doi.org/10.2337/dc18-0559
Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study
https://doi.org/10.2337/db18-301-or
Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study
https://doi.org/10.2337/db18-1029-p
1098-P: Treatment Satisfaction with Gla-300, IDeg-100, and Gla-100 in Insulin-Naïve T2DM: The BRIGHT and EDITION 3 Trials
https://doi.org/10.2337/db19-1098-p
Lower Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM on Oral Antihyperglycemic Therapy ± GLP-1RA—The BRIGHT Randomized Study
https://doi.org/10.2337/db18-1032-p
146-OR: Differences in HbA1c-Lowering Effect and Hypoglycemia Risk between Gla-300 and IDeg According to Renal Function in the BRIGHT Trial
https://doi.org/10.2337/db19-146-or
1090-P: Reaching ADA Glycemic Targets without Hypoglycemia during Titration with Gla-300 and IDeg in T2DM: Exploratory Analyses from BRIGHT
https://doi.org/10.2337/db19-1090-p
1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes
https://doi.org/10.2337/db19-1095-p
Funding for this research was provided by:
Sanofi